Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Optimal interventions to prevent or delay cognitive decline, mild cognitive impairment (MCI), or dementia are uncertain. Purpose: To summarize the evidence on efficacy and harms of over-the-counter (OTC) supplements to prevent or delay cognitive decline, MCI, or clinical Alzheimer-type dementia in adults with normal cognition or MCI but no dementia diagnosis. Data Sources: Multiple electronic databases from 2009 to July 2017 and bibliographies of systematic reviews. Study Selection: English-language trials of at least 6 months' duration that enrolled adults without dementia and compared cognitive outcomes with an OTC supplement versus placebo or active controls. Data Extraction: Extraction performed by a single reviewer and confirmed by a second reviewer; dual-reviewer assessment of risk of bias; consensus determination of strength of evidence. Data Synthesis: Thirty-eight trials with low to medium risk of bias compared ω-3 fatty acids, soy, ginkgo biloba, B vitamins, vitamin D plus calcium, vitamin C or β-carotene, multi-ingredient supplements, or other OTC interventions with placebo or other supplements. Few studies examined effects on clinical Alzheimer-type dementia or MCI, and those that did suggested no benefit. Daily folic acid plus vitamin B12 was associated with improvements in performance on some objectively measured memory tests that were statistically significant but of questionable clinical significance. Moderate-strength evidence showed that vitamin E had no benefit on cognition. Evidence about effects of ω-3 fatty acids, soy, ginkgo biloba, folic acid alone or with other B vitamins, β-carotene, vitamin C, vitamin D plus calcium, and multivitamins or multi-ingredient supplements was either insufficient or low-strength, suggesting that these supplements did not reduce risk for cognitive decline. Adverse events were rarely reported. Limitation: Studies had high attrition and short follow-up and used a highly variable set of cognitive outcome measures. Conclusion: Evidence is insufficient to recommend any OTC supplement for cognitive protection in adults with normal cognition or MCI. Primary Funding Source: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A systematic review of the use of supplements, including vitamins C, D and E, omega-3 fatty acids and ginkgo biloba, found little to no benefit in preventing cognitive decline, MCI or Alzheimer's dementia.138”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [138]
In the citing paper
“No single food, beverage, ingredient, vitamin or supplement has been proven to prevent or cure Alzheimer's or any other dementia.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [146]
Citations
Cites
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012244 · Cited by 813
Durga, J., van Boxtel, M. P., Schouten, E. G., Kok, F. J., Jolles, J., Katan, M. B., & Verhoef, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60109-3 · Cited by 758 · cited 1×
“8 mg) compared with placebo over 3 years (31).”
DeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 670
Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V., & Alexander, G. C. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.8581 · Cited by 658
Ginkgo biloba for cognitive impairment and dementia
Birks, J., & Grimley Evans, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 581
Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline
Yurko‐Mauro, K., McCarthy, D., Rom, D., Nelson, E. B., Ryan, A. S., Blackwell, A., Salem, N., Stedman, M., & MIDAS Investigators (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.01.013 · Cited by 579 · cited 5×
“One study used only docosahexaenoic acid (DHA) (17); all others used some combination of eicosapentaenoic acid (EPA) plus DHA.”
InfluentialPreventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment
Douaud, G., Refsum, H., de Jager, C. A., Jacoby, R., E. Nichols, T., Smith, S. M., & Smith, A. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301816110 · Cited by 515
de Jager, C. A., Oulhaj, A., Jacoby, R., Refsum, H., & Smith, A. D. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2758 · Cited by 457
Research works printed but not linked: 1
- Charemboon T, 2015, J Med Assoc Thai, 98, 508
Cited by
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
“A systematic review [40] of the use of supplements, including (but not limited to) C, D and E vitamins, omega-3 fatty acids, and ginkgo biloba, found little to no benefit of over-the-counter supplements in preventing cognitive decline, MCI or Alzheimer’s dementia.”
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Metadata
- Authors
- Butler, M., Nelson, V. A., Davila, H., Ratner, E., Fink, H. A., Hemmy, L. S., McCarten, J. R., Barclay, T. R., Brasure, M., & Kane, R. L.
- Affiliations
- University of Minnesota (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-01-02
- Volume
- 168
- Issue
- 1
- Pages
- 52-62
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2778293650
- Cited by
- 144
- References
- 52
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 17 · 2023: 16 · 2022: 17 · 2021: 25 · 2020: 20 · 2019: 21 · 2018: 11
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- over-the-counter supplements, cognitive decline, mild cognitive impairment, Alzheimer-type dementia, dementia prevention, omega-3 fatty acids, soybean, Ginkgo biloba, B vitamins, folic acid, vitamin B12, vitamin E, beta-carotene, vitamin C, multivitamins, memory, adverse events
- MeSH terms
- Alzheimer Disease, Nonprescription Drugs, Humans, Dietary Supplements, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. https://app.cochat.ai/papers/10.7326/m17-1530
- The paper
- Butler, M., Nelson, V. A., Davila, H., Ratner, E., Fink, H. A., Hemmy, L. S., McCarten, J. R., Barclay, T. R., Brasure, M., & Kane, R. L. (2018). Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Annals of Internal Medicine. https://doi.org/10.7326/m17-1530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.